title: Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC-MS/MS combined with iTRAQ technology.
abstract: To discover novel lung adenocarcinoma (AdC) biomarkers, isobaric tags for relative and absolute quantitation (iTRAQ)-tagging combined with 2D-LC-MS/MS analysis was used to identify differentially expressed plasma membrane proteins in lung AdC and paired paraneoplastic normal lung tissues (PNLTs) adjacent to tumors. In this study, significant caveolin-1 downregulation and integrin β1 upregulation was observed in primary lung AdC vs. PNLT. As there has been no report on the association of integrin β1 with lung AdC, immunohistochemical staining was performed to detect the expression of integrin β1 in an independent set of archival tissue specimens including 42 cases of PLNT, 46 cases of without lymph node metastasis primary AdC (non-LNM AdC) and 62 cases of LNM AdC; the correlation of their expression levels with clinicopathological characteristics and clinical outcomes were evaluated. Based on the data, upregulation of integrin β1 was significantly correlated with advanced clinical stage and lymph node metastasis. Integrin β1 overexpression was significantly associated with advanced clinical stage (P<0.05), lymph node metastasis (P<0.05), increased relapse rate (P<0.05) and decreased overall survival (P<0.05) in AdCs. Cox regression analysis indicated that integrin β1 overexpression is an independent prognostic factor. The data suggest that integrin β1 is a potential biomarker for LNM and prognosis of AdC and integrin β1 upregulation may play an important role in the pathogenesis of AdC.
authors.affiliation: Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China. zhangpf690421@csu.edu.cn
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Zhang
authors.forename: Gu-Qing
authors.initials: GQ
authors.lastname: Zeng
authors.forename: Lun-Zhao
authors.initials: LZ
authors.lastname: Yi
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Liu
authors.forename: Xun-Xun
authors.initials: XX
authors.lastname: Wan
authors.forename: Jia-Quan
authors.initials: JQ
authors.lastname: Qu
authors.forename: Jian-Huang
authors.initials: JH
authors.lastname: Li
authors.forename: Cui
authors.initials: C
authors.lastname: Li
authors.forename: Can-E
authors.initials: CE
authors.lastname: Tang
authors.forename: Rong
authors.initials: R
authors.lastname: Hu
authors.forename: Xu
authors.initials: X
authors.lastname: Ye
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.forename: Zhu-Chu
authors.initials: ZC
authors.lastname: Chen
authors.forename: Zhi-Qiang
authors.initials: ZQ
authors.lastname: Xiao
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality*; D000077192:Adenocarcinoma of Lung; D014408:Biomarkers, Tumor; D002853:Chromatography, Liquid; D005260:Female; D006801:Humans; D019012:Integrin beta1 / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D013534:Survival; D053719:Tandem Mass Spectrometry; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D019012:Integrin beta1